443 442
444 443
445 444
446 445
447 446
448 447
449 448
450 449
451 450
452 451
453 452
454 453
455 454
456 455
457 456
458 457
459 458
460 459
461 460
Contemporary Accounts in Drug Discovery and Development
Edited by
Xianhai Huang
InventisBio Co., Ltd., Florham Park, USA
Robert G. Aslanian
New Jersey City University, Jersey City, USA
Wayne H. Tang
Schrödinger Inc., New York, USA
This edition first published 2022 © 2022 John Wiley & Sons, Inc
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at http://www.wiley.com/go/permissions.
The right of Xianhai Huang, Robert G. Aslanian, and Wayne H. Tang to be identified as the authors of the editorial material in this work has been asserted in accordance with law.
Registered Office John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA
Editorial Office 111 River Street, Hoboken, NJ 07030, USA
For details of our global editorial offices, customer services, and more information about Wiley products visit us at www.wiley.com.
Wiley also publishes its books in a variety of electronic formats and by print‐on‐demand. Some content that appears in standard print versions of this book may not be available in other formats.
Limit of Liability/Disclaimer of Warranty In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of experimental reagents, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each chemical, piece of equipment, reagent, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.
Library of Congress Cataloging‐in‐Publication Data
Names: Huang, Xianhai, editor. | Aslanian, Robert G., editor. | Tang, Wayne H. (Wayne Haifeng), editor.
Title: Contemporary accounts in drug discovery and development / edited by Xianhai Huang, Robert G. Aslanian, Wayne H. Tang.
Other titles: Case studies in modern drug discovery and development.
Description: Second edition. | Hoboken, NJ : Wiley, 2022. | Preceded by Case studies in modern drug discovery and development / edited by Xianhai Huang, Robert G. Aslanian. 2012. | Includes bibliographical references and index.
Identifiers: LCCN 2021055890 (print) | LCCN 2021055891 (ebook) | ISBN 9781119627715 (cloth) | ISBN 9781119627852 (adobe pdf) | ISBN 9781119627814 (epub) | ISBN 9781119627784 (oBook)
Subjects: MESH: Drug Discovery | Drug Development
Classification: LCC RM301.25 (print) | LCC RM301.25 (ebook) | NLM QV 745 | DDC 615.1/9–dc23/eng/20211228
LC record available at https://lccn.loc.gov/2021055890 LC ebook record available at https://lccn.loc.gov/2021055891
Cover Design: Wiley
Cover Image: © Sergey Nivens/Shutterstock
Preface
It has been almost nine years now since the publication of the first edition of Case Studies in Modern Drug Discovery and Development in 2012. The book has been well received, in part for its breadth of topics including accounts of the discovery of life‐saving drugs. The purpose of the first edition of the book was to preserve knowledge of drug discovery and development at a time that small‐molecule drug discovery was seemingly at a crossroad and looking for direction. In the years since the publication of the first edition, we have been fortunate to witness the approval of many new drug products. In fact, 2018 witnessed a historic number of novel drug approvals by the FDA (a total of 59). Technology has advanced at an amazing pace in the past few years, which has enabled many formally untenable modalities, such as peptides, drug conjugates, antibodies, RNA, and vaccines, to provide new options for drug discovery. In addition, advances in basic science have also helped to accelerate
